Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 405

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Open access
Russo, Mariangela, Siravegna, Giulia, Blaszkowsky, Lawrence S., Corti, Giorgio, Crisafulli, Giovanni, Ahronian, Leanne G., Mussolin, Benedetta, Kwak, Eunice L., Buscarino, Michela, Lazzari, Luca, Valtorta, Emanuele, Truini, Mauro, Jessop, Nicholas A., Robinson, Hayley E., Hong, Theodore S., Mino-Kenudson, Mari, Di Nicolantonio, Federica, Thabet, Ashraf, Sartore-Bianchi, Andrea, Siena, Salvatore, Iafrate, A. John, Bardelli, Alberto, Corcoran, Ryan B.·2016·Cancer Discovery

Abstract

How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radiologic imaging to monitor the impact of individual oncogenic alterations on lesion-specific responses. Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1K57T mutation as a novel mechanism of acquired resistance. This lesion regressed upon treatment with panitumumab and the MEK inhibitor trametinib. In circulating tumor DNA (ctDNA), mutant MEK1 levels declined with treatment, but a previously unrecognized KRASQ61H mutation was also identified that increased despite therapy. This same KRAS mutation was later found in a separate nonresponding metastasis. In summary, parallel analyses of tumor biopsies and serial ctDNA monitoring show that lesion-specific radiographic responses to subsequent targeted therapies can be driven by distinct resistance mechanisms arising within separate tumor lesions in the same patient. Significance: Molecular heterogeneity ensuing from acquired resistance drives lesion-specific responses to subsequent targeted therapies. Analysis of a single-lesion biopsy is inadequate to guide selection of subsequent targeted therapies. ctDNA profiles allow the detection of concomitant resistance mechanisms residing in separate metastases and assessment of the effect of therapies designed to overcome resistance. Cancer Discov; 6(2); 147–53. ©2015 AACR. See related commentary by Hiley and Swanton, p. 122. This article is highlighted in the In This Issue feature, p. 109

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-1283

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 405

Metadata

Authors
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., Valtorta, E., Truini, M., Jessop, N. A., Robinson, H. E., Hong, T. S., Mino-Kenudson, M., Di Nicolantonio, F., Thabet, A., Sartore-Bianchi, A., Siena, S., Iafrate, A. J., Bardelli, A., & Corcoran, R. B.
Venue
Cancer Discovery
Published
2016-02-01
Volume
6
Issue
2
Pages
147-153
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2216675461
Cited by
405
References
23
FWCI
15.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-1283
The paper
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., Valtorta, E., Truini, M., Jessop, N. A., Robinson, H. E., Hong, T. S., Mino-Kenudson, M., Di Nicolantonio, F., Thabet, A., Sartore-Bianchi, A., . . . Corcoran, R. B. (2016). Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-1283

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.